Popular search terms:
Search Results
61 results found-
9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/product-monograph-afluria-20232024-sep-5-2023-v2.pdf -
CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
https://www.cslseqirus.ca/news/seqirus-commends-naci-for-preferential-influenza-for-adults-65-and-older -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2023-pms/2023-fluad-product-monograph-12-apr-2023.pdf -
FLUCELVAX® QUAD Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures) Page 8 of 30 Percentages of Subjects with Any (Severe) Solicited Reactions3 18 to less than 65 years of age ≥ 65 years of age Trivalent Influenza Trivalent FLUCELVAX® FLUCELVAX® QUAD Vaccine Influenza Vaccine QUAD N=663 TIV1c TIV2c TIV1c TIV2c N=656 N=330 N=327 N=340 N=336 Fever:
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2023-pms/2023-flucelvax-product-monograph-12-apr-2023.pdf -
Abbreviation Term AE Adverse event AEFI Adverse event following immunization ART Antiretroviral therapy CAEFISS Canadian Adverse Events Following Immunization Surveillance System CI Confidence interval CIG Canadian Immunization Guide DIN Drug Identification Number FFU Fluorescent focus units GBS Guillain-Barré syndrome GMT Geometric mean titre GMTR Geometric mean titre ratio HA Hemagglutinin HAART Highly active antiretroviral therapy HCW Health care worker HIV Human immunodeficiency virus Ig Immunoglobulin IIV Inactivated influenza vaccine IIV3 Trivalent inactivated influenza vaccine IIV3-Adj Adjuvanted trivalent inactivated influenza vaccine (egg-based) IIV3-HD High-dose trivalent inactivated influenza vaccine (egg-based) IIV3-SD Standard-dose trivalent inactivated influenza vaccine (egg-based) IIV4 Quadrivalent inactivated influenza vaccine Mammalian cell culture-based quadrivalent inactivated influenza IIV4-cc vaccine IIV4-HD High-dose quadrivalent inactivated influenza vaccine (egg-based) IIV4-SD Standard-dose quadrivalent inactivated influenza vaccine (egg-based) ILI Influenza-like illness
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/naci-2022-2023-statement.pdf -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.ca/ -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news -
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Amongamong Healthcare Personnel Aged 18-64 Years:
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-fr/naci-2022-2023-statement-fr.pdf